SFP
NBIX icon

Santa Fe Partners’s Neurocrine Biosciences NBIX Stock Holding History

Santa Fe Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-46,595
Closed -$1.85M – 541
2015
Q3 		$1.85M Buy
46,595
+17,841
+62% +$862K 0.25% 178
2015
Q2 		$1.37M Buy
+28,754
New +$1.22M 0.19% 224

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Santa Fe Partners's NBIX Position: Q4 2015 in Review

Santa Fe Partners sold out of Neurocrine Biosciences (NBIX) in Q4 2015, closing a stake of 46,595 shares — an estimated $1.85M sold.

Santa Fe Partners first reported a position in NBIX in Q2 2015 and held it in 2 quarters. The position peaked at $1.85M in Q3 2015. 218 funds tracked by Wall St. Rank hold NBIX as of Q4 2015.

  • Santa Fe Partners reported no remaining Neurocrine Biosciences position as of Q4 2015 after selling out during the quarter.
  • Santa Fe Partners sold 46,595 Neurocrine Biosciences shares in Q4 2015, an estimated $1.85M.
  • Santa Fe Partners first reported a position in Neurocrine Biosciences in Q2 2015 and held it in 2 quarters.
  • Santa Fe Partners's Neurocrine Biosciences position peaked at $1.85M in Q3 2015.
  • 218 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2015.

Based on Santa Fe Partners's 13F filing for Q4 2015, filed 12 Feb 2016.